Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone

: Tornio A, Niemi M, Neuvonen PJ, Backman JT

Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS

: 2008

: Drug Metabolism and Disposition

: DRUG METABOLISM AND DISPOSITION

: DRUG METAB DISPOS

: 36

: 1

: 73

: 80

: 8

: 0090-9556

DOI: https://doi.org/10.1124/dmd.107.018010

We studied the effects of the CYP2C8 inhibitor trimethoprim and CYP2C8 genotype on the pharmacokinetics of the antidiabetic pioglitazone. In a randomized crossover study, 16 healthy volunteers with the CYP2C8*1/*1 (n = 8), *1/*3 (n = 5), or *3/*3 (n = 3) genotype ingested 160 mg of trimethoprim or placebo twice daily for 6 days. On day 3, they ingested 15 mg of pioglitazone. The effects of trimethoprim on pioglitazone were characterized in vitro. Trimethoprim raised the area under the plasma pioglitazone concentration-time curve (AUC(0 ->infinity)) by 42% (p < 0.001) and decreased the formation rates of pioglitazone metabolites M-IV and M-III (p < 0.001). During the placebo phase, the weight-adjusted AUC(0 ->infinity) of pioglitazone was 34% smaller in the CYP2C8*3/*3 group and 26% smaller in the CYP2C8*1/*3 group than in the CYP2C8*1/*1 group (p < 0.05). Trimethoprim inhibited M-IV formation in vitro (inhibition constant 38.2 mu M), predicting the in vivo interaction. In conclusion, drug interactions and pharmacogenetics affecting the CYP2C8 enzyme may change the safety of pioglitazone.